首页>
外国专利>
KIF5B gene and RET gene fusion gene and method for determining the effectiveness of cancer treatment targeting the fusion gene
KIF5B gene and RET gene fusion gene and method for determining the effectiveness of cancer treatment targeting the fusion gene
展开▼
机译:KIF5B基因和RET基因融合基因以及确定针对该融合基因的癌症治疗效果的方法
展开▼
页面导航
摘要
著录项
相似文献
摘要
In order to identify a gene that can serve as an indicator for predicting the effectiveness of a drug treatment of cancer and to provide a novel method for predicting the effectiveness of a drug treatment targeting said gene, lung adenocarcinomas were subjected to whole-transcriptome sequencing. As a result, in-frame fusion transcripts between the KIF5B gene and the RET gene were identified. The KIF5B-RET gene fusions were detected in 6 out of 319 (2%) LADC specimens from Japanese individuals and 1 out of 80 (1%) LADC specimens from U.S.A. individuals. None of the seven subjects revealed known activating mutations such as EGFR, KRAS or ALK oncogenes; thus, said gene fusions were found to be responsible mutations (driver mutations) for oncogenesis. Since said gene fusions are considered to induce constitutive activation of RET tyrosine kinase protein, it was found that treatments with RET tyrosine kinase inhibitors are effective in patients with detection of said gene fusions.
展开▼